Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma：a Single-center, Exploratory Clinical Study

NCT04397770 Phase 2 UNKNOWN

It is a single-center,exploratory clinical trial aimed to evaluate the objective response rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma.

Details

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 2
Status	UNKNOWN
Enrolment	40
Start date	2020-05
Completion	2023-02

Conditions

• Melanoma

Interventions

• SHR1210
• apatinib mesylate
• Temozolomide Injection

Primary outcomes

• ORR — Through study uncompletion, an average of 1 year
  Objective Response Rate